Expression of endothelin in experimental myocardial infarction in a changed concentration of FGF and VEGF
Abstract
The objective of the work was to study the expression of endothelin in experimental myocardial infarction, and. to assess the impact on its altered concentrations of growth factors. The study was performed on a model of myocardial infarction. The experiment was conducted, on 150 female Wistar rats. Five groups of animals were studied: control group, the increased concentration FGF2 and. VEGF, the decreased concentration of FGF or VEGF. Excretion of animal experiments were conducted in the period from 1 to 30 days. The heart of the experimental animal was fixed in a solution of 10% neutral formalin. His-tochemical staining was used. Primary antibodies to endothelin ET-1/2/3 (H-38) rabbit polyclonal IgG (Santa Cruz, Cat. N Sc-98727, Lot # G2209). We determined that in control group there was a stain on endothelin in the area of myocardial infarction from the 1st to the 7th day with a peak on day 3. The use of growth factors increased the staining of the border and. infarct zones on the 1st to the 14th days with a maximum of day 3. The use of antibodies to growth factors reduced the stain of the in farcted area early after myocardial infarction (days 1 to 3), to the 7th day of the stain intensity increases sharply, reaching a maximum, and. to the 14th day again declined. Thus, we established the dynamics of expression of endothelin in the myocardium when the ischemic injury and. heart attack, as well as the significant stimulatory effect of growth factors FGF2 and. VEGF on the expression of endothelin in the area of ischemic damage at experimental myocardial infarction.
About the Authors
M. G. Shurygin
ФГБУ «Научный центр реконструктивной и восстановительной хирургии» СО РАМН, ФГБУН Иркутский научный центр СО РАН
Russian Federation
Russian Federation
I. A. Shurygina
ФГБУ «Научный центр реконструктивной и восстановительной хирургии» СО РАМН, ФГБУН Иркутский научный центр СО РАН
Russian Federation
Russian Federation
N. N. Dremina
ФГБУ «Научный центр реконструктивной и восстановительной хирургии» СО РАМН, ФГБУН Иркутский научный центр СО РАН
Russian Federation
Russian Federation
O. V. Kanya
ФГБУ «Научный центр реконструктивной и восстановительной хирургии» СО РАМН, ФГБУН Иркутский научный центр СО РАН
Russian Federation
Russian Federation
References
1. Гозмаков О.А. Эндотелин в кардиологии: молекулярные, физиологические и патологические аспекты (обзор) // Кардиология. — 2001. — № 2. — С. 50-58.
2. Мордовин В.Ф., Рипп Т.М., Соколов С.Е. и др. Динамика показателей эндотелийзависимой вазодилатации и гипотензивная эффективность эналаприла у пациентов с артериальной гипертензией // Кардиология. - 2001. - № 6. - С. 31-33.
3. Патарая С.А., Преображенский Д.В., Сидоренко Б.А., Масенко В.П. Биохимия и физиология семейства эндотелинов // Кардиология. — 2000. — Т. 40, № 6. - С. 78-85.
4. Суворов А.В., Горева В.В., Суворов М.А. Изменение липидного профиля, пероксидазных свойств крови и уровня эндотелина-1 у больных стенокардией напряжения при лечении нифедипином GITS и фелодипином // Нижнегородский мед. журн. — 2002. — № 3. — С. 7—11.
5. Шурыгин М.Г., Шурыгина И.А. Фактор роста фибробластов как стимулятор ангиогенеза при инфаркте миокарда // Бюл. СО РАМН. — 2010. — Т. 30, № 6. — С. 89 — 92.
6. Шурыгин М.Г., Шурыгина И.А., Каня О.В. Динамика плотности рецепторов к фактору роста фибробластов при экспериментальном инфаркте миокарда // Сибирский медицинский журнал. — 2010. — № 2. — С. 20 — 22.
7. Bohm F., Beltran E., Pernow J. Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition // J. Intern. Med. — 2005. — Vol. 257. — P. 263 — 271.
8. Inoue A., Yanagisawa M., Kimura S. et al.The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes // Proc. Natl. Acad. Sci. USA. — 1989. — Vol. 86, N 8. — P. 2863 — 2867.
9. Itoh Y., Yanagisawa M., Ohkubo S. et al. Cloning and sequence analysis of cDNA encoding the precursor of a human endothelium-derived vasoconstrictor peptide, endothelin: identity of human and porcine endothelin // FEBS Lett. — 1988. — Vol. 231, N 2. — P. 440 — 444.
10. Levin E.R. Endothelins // N. Engl. J. Med. — 1995. — Vol. 333, N 6. — P. 356 — 363.
11. Rothermund L., Pinto Y.M., Hocher B. et al. Cardiac endothelin system impairs left ventricular function in rennin-dependent hypertension via sarcoplasmic reticulum Ca2+ uptake // Circulation. -2000. - Vol. 102. - P. 1582-1588.
12. Spinar J., Spinarova L., Vitovec J. et al. Big endothelin and chronic heart failure // Vnitr. Lek. - 2002. - Vol. 48. - P. 3-7.
13. Willey K.E. Davenport A.P. Nitric oxide-medulation of the endothelin-1 signaling pathway in the human cardiovascular system // Brit. J. Pharmacology. - 2001. - Vol. 132. - P. 213-220. 1 4. Yanagasawa M. , Kurihara H., Kimura S. , Tomobe Y. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells // Nature. - 1988. - Vol. 332, N 6163. -P. 411-415.
14. Yanagisawa M., Masaki T. Molecular biology and biochemistry of the endothelins // Trend. Pharmacol. Sci. - 1989. - Vol. 10. - P. 374-378.
Review
For citations:
Shurygin M.G., Shurygina I.A., Dremina N.N., Kanya O.V. Expression of endothelin in experimental myocardial infarction in a changed concentration of FGF and VEGF. Acta Biomedica Scientifica. 2013;(1):125-129. (In Russ.)
Views:
434
Email this article 
